A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide Doxorubicin and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
-
- STATUS
- Not Recruiting
-
- End date
- Jul 10, 2024
-
- participants needed
- 875
-
- sponsor
- Hoffmann-La Roche
Updated on 2 June 2021
The University of Adelaide - The Queen Elizabeth Hospital (TQEH) (0.0 mi away) Contact
cyclophosphamide
rituximab
vincristine
ejection fraction
prednisone
doxorubicin
b-cell lymphoma
high grade b-cell lymphoma
Summary
This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
Details
| Condition | Diffuse Large B-Cell Lymphoma, diffuse large cell lymphoma, diffuse large b cell lymphoma |
|---|---|
| Treatment | Rituximab, cyclophosphamide, prednisone, vincristine, doxorubicin, Polatuzumab Vedotin, Vincristine Placebo, Polatuzumab vedotin Placebo |
| Clinical Study Identifier | NCT03274492 |
| Sponsor | Hoffmann-La Roche |
| Last Modified on | 2 June 2021 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Browse trials for
cyclophosphamide
rituximab
vincristine
ejection fraction
prednisone
doxorubicin
b-cell lymphoma
high grade b-cell lymphoma
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer